Laboratory Publications
A Phase 2 Prospective Study Evaluating Low-Dose Deferasirox in Patients with Low-Risk Myelodysplastic Syndrome Resistant or Relapsing after Erythropoietin Stimulating Agents (LODEFI) - Archive ouverte HAL
Poster De Conférence Année : 2024

A Phase 2 Prospective Study Evaluating Low-Dose Deferasirox in Patients with Low-Risk Myelodysplastic Syndrome Resistant or Relapsing after Erythropoietin Stimulating Agents (LODEFI)

Sylvain Thépot
Frédéric Garban
Sébastien Maury
Kamel Laribi
Pirayeh Eftekhari
  • Fonction : Auteur
Geoffroy Venton
Stéphane Cheze
  • Fonction : Auteur
Mathieu Molimard
Fichier non déposé

Dates et versions

hal-04875903 , version 1 (09-01-2025)

Identifiants

Citer

Meunier Mathieu, Sylvain Thépot, Stanislas Nimubona, Mélanie Veloso, Thibaud Lefebvre, et al.. A Phase 2 Prospective Study Evaluating Low-Dose Deferasirox in Patients with Low-Risk Myelodysplastic Syndrome Resistant or Relapsing after Erythropoietin Stimulating Agents (LODEFI). The 66th ASH Annual Meeting, Oct 2024, San Diego (CA), United States. 144 (Supplement 1), pp.1826-1826, 2024, ⟨10.1182/blood-2024-198104⟩. ⟨hal-04875903⟩
25 Consultations
0 Téléchargements

Altmetric

Partager

  • More